Perrigo
Perrigo Company plc is a global consumer self-care and over-the-counter healthcare company that develops, manufactures, and distributes store-brand and branded self-care products across North America and Europe. Operating primarily through its Consumer Self-Care Americas and Consumer Self-Care International segments, the company supplies products spanning upper respiratory relief, pain and sleep aids, digestive health, nutrition and infant formula, oral care, skin care, and women's health. Following the divestment of its prescription generic pharmaceuticals unit, Perrigo focused exclusively on self-care categories, retailing both national brands such as Compeed, Solpadeine, and Coldrex and private-label equivalents sold by major pharmacy chains, supermarkets, and mass merchandisers. Revenue is driven by high-volume retail distribution, store-brand market share gains, and consumer demand for affordable non-prescription remedies. Legally domiciled in Dublin, Ireland, with operational headquarters in Grand Rapids, Michigan, Perrigo is listed on the New York Stock Exchange, employs roughly eight to nine thousand people, and generates over four billion dollars in annual revenue.
3 of the funds FundTelligence covers report a position in Perrigo.
- Legal name
- Perrigo Co PLC
- Sector
- Health Care
- Country
- Ireland
- Funds holding it
- 3
Funds holding Perrigo
- Mercer Global Small Cap Equity Fund — Mercer · 0.1 % (full portfolio disclosed, December 2025)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.02 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.01 % (partially disclosed portfolio, June 2026)